Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
出版年份 2020 全文链接
标题
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-12
DOI
10.1002/ijc.33146
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data
- (2019) Jie Ying et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Medical treatment for cholangiocarcinoma
- (2019) Jorge Adeva et al. LIVER INTERNATIONAL
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
- (2019) John N Primrose et al. LANCET ONCOLOGY
- Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
- (2019) Cindy Neuzillet et al. EUROPEAN JOURNAL OF CANCER
- LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
- (2019) G K Abou-Alfa et al. ANNALS OF ONCOLOGY
- LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
- (2019) A Vogel et al. ANNALS OF ONCOLOGY
- A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
- (2018) Yi Zheng et al. BRITISH JOURNAL OF CANCER
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- (2017) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues
- (2015) Bertrand Brieau et al. CANCER
- Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
- (2015) S. Cereda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
- (2015) Lorenzo Fornaro et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
- (2014) L Fornaro et al. BRITISH JOURNAL OF CANCER
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
- (2013) Eiichiro Suzuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
- (2010) Takashi Sasaki et al. INVESTIGATIONAL NEW DRUGS
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer
- (2009) Takashi Sasaki et al. ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now